Brokers Set Expectations for Arcellx FY2026 Earnings

Arcellx, Inc. (NASDAQ:ACLX) – Equities research analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for Arcellx in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst R. Bienkowski expects that the company will earn ($2.65) per share for the year. The consensus estimate for Arcellx’s current full-year earnings is ($1.58) per share.

Arcellx (NASDAQ:ACLX) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($0.29). The firm had revenue of $8.13 million for the quarter, compared to analysts’ expectations of $19.51 million. Arcellx had a negative net margin of 25.94% and a negative return on equity of 8.28%.

Separately, Scotiabank cut their price target on shares of Arcellx from $133.00 to $93.00 and set a “sector outperform” rating on the stock in a research note on Friday, May 9th. Thirteen equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Arcellx currently has an average rating of “Buy” and a consensus price target of $111.33.

Arcellx Stock Down 0.4%

NASDAQ:ACLX opened at $66.61 on Tuesday. The company has a market cap of $3.67 billion, a P/E ratio of -93.82 and a beta of 0.28. Arcellx has a fifty-two week low of $47.86 and a fifty-two week high of $107.37. The firm’s 50 day moving average is $61.41 and its two-hundred day moving average is $68.40.

Insider Activity

In other news, Director Kavita Patel sold 1,500 shares of the firm’s stock in a transaction on Tuesday, April 8th. The shares were sold at an average price of $57.50, for a total value of $86,250.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. In the last 90 days, insiders have sold 6,000 shares of company stock valued at $377,655. Company insiders own 8.35% of the company’s stock.

Institutional Investors Weigh In On Arcellx

A number of large investors have recently added to or reduced their stakes in the company. FMR LLC grew its holdings in Arcellx by 22.8% during the 4th quarter. FMR LLC now owns 7,956,633 shares of the company’s stock valued at $610,194,000 after purchasing an additional 1,477,360 shares in the last quarter. Gilead Sciences Inc. acquired a new stake in Arcellx during the 4th quarter valued at $515,418,000. Paradigm Biocapital Advisors LP grew its holdings in Arcellx by 2.8% during the 1st quarter. Paradigm Biocapital Advisors LP now owns 4,492,032 shares of the company’s stock valued at $294,677,000 after purchasing an additional 120,431 shares in the last quarter. Vanguard Group Inc. grew its holdings in Arcellx by 19.7% during the 1st quarter. Vanguard Group Inc. now owns 3,985,156 shares of the company’s stock valued at $261,426,000 after purchasing an additional 655,064 shares in the last quarter. Finally, RA Capital Management L.P. grew its holdings in Arcellx by 8.9% during the 1st quarter. RA Capital Management L.P. now owns 3,036,527 shares of the company’s stock valued at $199,196,000 after purchasing an additional 249,200 shares in the last quarter. 96.03% of the stock is owned by institutional investors and hedge funds.

About Arcellx

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company’s lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).